DD210843A5 - Verfahren zur herstellung eines arzneimittels zur behandlung von neoplasma-erkrankungen - Google Patents

Verfahren zur herstellung eines arzneimittels zur behandlung von neoplasma-erkrankungen Download PDF

Info

Publication number: DD210843A5
Authority: DD; German Democratic Republic
Prior art keywords: herba; treatment; infusion; diseases; medicament
Prior art date: 1982-06-16

Application number

DD83252009A

Other languages

German (de)

English (en)

Inventor

Mihai Danila

Original Assignee

Biofarm Fab Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-06-16

Filing date

1983-06-14

Publication date

1984-06-27

1983-06-14 Application filed by Biofarm Fab Medicament filed Critical Biofarm Fab Medicament

1984-06-27 Publication of DD210843A5 publication Critical patent/DD210843A5/de

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
238000000034 method Methods 0.000 title claims abstract description 9
239000003814 drug Substances 0.000 title claims description 13
201000010099 disease Diseases 0.000 title claims description 10
238000004519 manufacturing process Methods 0.000 title description 2
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims abstract description 12
238000001802 infusion Methods 0.000 claims abstract description 12
241000196324 Embryophyta Species 0.000 claims abstract description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
235000019441 ethanol Nutrition 0.000 claims abstract description 6
RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims abstract description 5
239000007788 liquid Substances 0.000 claims abstract description 5
229960000907 methylthioninium chloride Drugs 0.000 claims abstract description 5
238000002360 preparation method Methods 0.000 claims abstract description 5
ZVNPWFOVUDMGRP-UHFFFAOYSA-N 4-methylaminophenol sulfate Chemical compound OS(O)(=O)=O.CNC1=CC=C(O)C=C1.CNC1=CC=C(O)C=C1 ZVNPWFOVUDMGRP-UHFFFAOYSA-N 0.000 claims abstract description 4
241000581692 Potentilla reptans Species 0.000 claims abstract description 4
238000000605 extraction Methods 0.000 claims abstract description 4
238000002156 mixing Methods 0.000 claims abstract description 4
241000219823 Medicago Species 0.000 claims abstract description 3
230000002195 synergetic effect Effects 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 4
241000693827 Helleborus niger Species 0.000 claims description 3
239000007903 gelatin capsule Substances 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 3
239000002775 capsule Substances 0.000 abstract description 16
206010028980 Neoplasm Diseases 0.000 abstract description 7
229910002007 uranyl nitrate Inorganic materials 0.000 abstract description 4
208000035269 cancer or benign tumor Diseases 0.000 abstract description 3
239000003795 chemical substances by application Substances 0.000 abstract description 2
239000012530 fluid Substances 0.000 abstract description 2
239000001828 Gelatine Substances 0.000 abstract 1
229920000159 gelatin Polymers 0.000 abstract 1
235000019322 gelatine Nutrition 0.000 abstract 1
238000002386 leaching Methods 0.000 abstract 1
239000000243 solution Substances 0.000 description 13
229940098465 tincture Drugs 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229940079593 drug Drugs 0.000 description 4
208000017604 Hodgkin disease Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
235000021152 breakfast Nutrition 0.000 description 3
CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 3
GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002803 maceration Methods 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
206010000830 Acute leukaemia Diseases 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
241000527994 Cyclotella gamma Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
208000001688 Herpes Genitalis Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
240000004658 Medicago sativa Species 0.000 description 1
235000010624 Medicago sativa Nutrition 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
208000012896 Peritoneal disease Diseases 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
206010038848 Retinal detachment Diseases 0.000 description 1
208000037063 Thinness Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
230000000574 ganglionic effect Effects 0.000 description 1
201000004946 genital herpes Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
201000006812 malignant histiocytosis Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
208000008423 pleurisy Diseases 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
230000004264 retinal detachment Effects 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000003582 thrombocytopenic effect Effects 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
206010048828 underweight Diseases 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/50—Fumariaceae (Fumitory family), e.g. bleeding heart
- A61K36/505—Corydalis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Medical Informatics (AREA)
Botany (AREA)
Alternative & Traditional Medicine (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DD83252009A 1982-06-16 1983-06-14 Verfahren zur herstellung eines arzneimittels zur behandlung von neoplasma-erkrankungen DD210843A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
RO82107893A RO81783A3 (fr)	1982-06-16	1982-06-16	Medicament pour le traitement de la maladie neoplastique

Publications (1)

Publication Number	Publication Date
DD210843A5 true DD210843A5 (de)	1984-06-27

Family

ID=20111710

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD83252009A DD210843A5 (de)	1982-06-16	1983-06-14	Verfahren zur herstellung eines arzneimittels zur behandlung von neoplasma-erkrankungen

Country Status (8)

Country	Link
EP (1)	EP0111529B1 (fr)
CA (1)	CA1203167A (fr)
DD (1)	DD210843A5 (fr)
DE (1)	DE3366025D1 (fr)
IL (1)	IL68896A0 (fr)
IT (1)	IT1161934B (fr)
RO (1)	RO81783A3 (fr)
WO (1)	WO1984000005A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR3015481B1 (fr) *	2013-12-20	2016-08-12	Etat Francais Represente Par Le Delegue General Pour L'armement	Utilisation de composes de diaminophenothiazinium en tant qu'agents de prevention, reduction ou suppression d'une radiotoxicite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2244468A1 (en) *	1973-07-31	1975-04-18	Passwater Richard	Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids

1982
- 1982-06-16 RO RO82107893A patent/RO81783A3/fr unknown
1983
- 1983-05-26 DE DE8383901948T patent/DE3366025D1/de not_active Expired
- 1983-05-26 EP EP83901948A patent/EP0111529B1/en not_active Expired
- 1983-05-26 WO PCT/RO1983/000001 patent/WO1984000005A1/fr not_active Ceased
- 1983-06-06 IL IL68896A patent/IL68896A0/xx unknown
- 1983-06-14 IT IT21614/83A patent/IT1161934B/it active
- 1983-06-14 DD DD83252009A patent/DD210843A5/de unknown
- 1983-06-15 CA CA000430434A patent/CA1203167A/fr not_active Expired

Also Published As

Publication number	Publication date
IT8321614A0 (it)	1983-06-14
RO81783A3 (fr)	1984-07-17
IT1161934B (it)	1987-03-18
EP0111529B1 (en)	1986-09-10
DE3366025D1 (en)	1986-10-16
WO1984000005A1 (fr)	1984-01-05
CA1203167A (fr)	1986-04-15
RO81783B1 (ro)	1984-03-08
EP0111529A1 (fr)	1984-06-27
IL68896A0 (en)	1983-10-31

Publication	Publication Date	Title
EP0857064B1 (fr)	2002-11-27	Preparations pharmaceutiques stabilisees contenant de l'hormone thyroidienne
DE3328262A1 (de)	1984-03-01	Arzneimittelzubereitung zur besserung von krebssymptomen
DE1902227A1 (de)	1969-09-04	Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner Herstellung
DE3022281C2 (de)	1985-07-18	Von Alkaloiden befreiter wäßriger Extrakt aus Aconitwurzeln und diesen Extrakt als Wirkstoff enthaltende pharmazeutische Zusammensetzung
EP0435913A1 (fr)	1991-07-10	Comprime effervescent.
DE68906765T2 (de)	1993-09-02	Zusammensetzung mit einem extrakt,das durch extraktion mit einem wasserhaltigen organischen loesungsmittel erhalten wurde und verfahren zu seiner herstellung.
DE10235465A1 (de)	2003-08-07	Neue chinesische Kräuterzusammensetzung zur Verbesserung der Blutzirkulation sowie Verfahren zum Herstellen derselben
DE1915798C3 (de)	1978-04-27	Antacidum-Präparat in Form einer wäßrigen Suspension
DE2434849C2 (de)	1986-03-20	Herzstärkende Dosierungseinheit mit Gelatinekapsel
DE2126533A1 (de)	1972-12-14	Verfahren zur Herstellung pharma zeutischer Zubereitungen
DD210843A5 (de)	1984-06-27	Verfahren zur herstellung eines arzneimittels zur behandlung von neoplasma-erkrankungen
DE3818022C2 (de)	1994-04-28	Weichgelatinekapsel
DE19603788B4 (de)	2005-12-22	Wirkstoffextrakt aus Teufelskrallenwurzel, diesen enthaltendes human- oder veterinärmedizinisches Präparat, Verfahren zur Herstellung eines hochkonzentrierten Extraktes aus Radix Harpagophyti oder Herba und Radix Scrophularia sowie dessen Verwendung
DE69533742T2 (de)	2005-10-27	Verwendung von Prolin und/oder Derivaten als Mittel gegen Hepatitis
DE2416216A1 (de)	1974-10-24	Pharmazeutische zusammensetzung, verfahren zu deren herstellung und verwendung eines vehiculums dafuer
DE3225056A1 (de)	1984-01-05	Arzneimittel, welches als wirkstoff den zerkleinerten samen von bockshornklee (trigonella foenum-graecum) enthaelt, verfahren zu dessen herstellung sowie verwendung desselben
DE2518509C3 (de)	1981-02-19	Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin
DE69526111T2 (de)	2002-07-18	Zusammensetzung zur behandlung von endometriose, welche ein salz eines edelmetalles und mel cum sale enthält
DE10238161A1 (de)	2004-02-26	Mineralstoff-Ampulle für die mucosale und topische Wirkstoffapplikation
DE2635293A1 (de)	1977-05-12	Salzgemisch, insbesondere leicht assimilierbares arzneimittelgemisch mit erhoehter loeslichkeit, enthaltend kalziumsalze und/oder magnesiumsalze
DE102024107455A1 (de)	2025-09-18	Leber-schützende zusammensetzung
DE2015877A1 (de)	1970-10-29	Arzneimittel
DE651597C (de)	1937-10-16	Verfahren zur Darstellung haltbarer Hormonpraeparate
DE3234366A1 (de)	1984-03-22	Arzneimittel, insbesondere zur krebstherapie
DE1767447C (de)	1972-09-14	Peroral verabreichbares, lagerfähiges pharmaceutisches Präparat enthaltend 5,6-Benzimidazol-Cobamid-Coenzym als aktiven Bestandteil